MOUNTAIN VIEW, CA--(Marketwired - Apr 25, 2016) - Hansen Medical®, Inc. (NASDAQ: HNSN), the global leader in intravascular robotics, today announced it will exhibit its Magellan™ Robotic System at the Charing Cross International Symposium in London, United Kingdom from April 26th to April 29th.
At the 38th annual symposium, the Magellan Robotic System and family of Magellan Robotic Catheters will be showcased and available for demonstrations at exhibit booth #215. Hansen Medical also anticipates that intravascular robotics will be discussed during the following sessions at Charing Cross:
April 26, 14:40, Robotic-assisted endovascular aneurysm repairs: improved efficiency compared to manual techniques for contralateral gate cannulation- Celia Riga, MD (London, UK)
April 27, 10:40, Case experience of iliac artery treatment with robotic hybrid approach- Fabien Thaveau, MD (Strasbourg, France)
April 27, 12:10, The Magellan Robotic Catheter eKit and potential for radiation dose reduction- Celia Riga, MD (London, UK)
April 28, 08:14, Improving procedural success in complex pathologies with robotics and advanced imaging - Barry Katzen, MD (Miami, US)
April 28, 08:30, Successful use of robotics in failed treatment of central venous stenosis - Alan Lumsden, MD (Houston, US)
April 28, 08:37, Inferior vena cava filter retrieval with robotics - Alan Lumsden, MD (Houston, US)
April 28, 09:37, Robotic benefits for endovascular procedures - Celia Riga, MD (London, UK)
April 28, 14:33, Methods to reduce radiation exposure during endovascular procedures - Barry Katzen, MD (Miami, US)
April 28, 15:45, The role of robotics in advanced endovascular procedures, Celia Riga, MD, (London, UK)
Additionally, Hansen Medical will host two physician presentations at its booth as a part of CX Imaging Day. These will focus on new clinical data and experiences with the current system and insights from Dr. Lumsden about his research with future robotic technology. The presentations include:
April 28, 12:30, Clinical Experiences with Intravascular Robotics, Barry Katzen, MD (Miami, US) (Hansen Booth 215)
April 28, 15:45, Flexible Robotics with Electromagnetic Tracking and the Impacts of Safety & Efficiency, Alan Lumsden, MD (Houston, US) (Hansen Booth 215)
"We are looking forward to having a strong presence at Charing Cross this year and are eager to connect with the vascular and endovascular community," said Cary Vance, Hansen Medical's President and Chief Executive Officer. "Our present Magellan users have gained great insights in clinical and research applications both with current and future technology, and we positively anticipate the new data and case reports that they will highlight during the symposium."
The Magellan Robotic System is an advanced technology that drives Magellan Robotic Catheters and guide wires during minimally-invasive, endovascular procedures. Magellan is designed to offer procedural predictability, precision, and catheter stability as physicians navigate inside blood vessels and deliver therapy. Image-guided medical procedures using interventional fluoroscopy, while growing rapidly, are the leading source of occupational ionizing radiation exposure for medical personnel1. Magellan's remote workstation allows physicians to control robotic catheters and guide wires while seated away from the radiation field, which has been shown to reduce radiation exposure for the physician by as much as 95% in complex endovascular procedures2.
About the Magellan™ Robotic System
Hansen Medical's Magellan Robotic System is intended to be used to facilitate navigation in the peripheral vasculature and subsequently provide a conduit for manual placement of therapeutic devices. The Magellan Robotic System is designed to deliver predictability, control and catheter stability to endovascular procedures. Since its commercial introduction in the U.S. and Europe, the Magellan Robotic System has demonstrated its clinical versatility in many cases in a broad variety of peripheral vascular procedures globally. The Magellan Robotic System offers several important features including:
Provides predictability, control and catheter stability as a physician navigates a patient's peripheral vasculature and then provides a conduit for manual treatment of vascular disease with standard therapeutic devices.
Is designed to enable more predictable procedure times and increased case throughput potentially allowing hospitals to improve utilization within their vascular business line.
Employs an open architecture designed to allow for the subsequent use of many therapeutic devices on the market today.
Is designed to potentially reduce physician radiation exposure and fatigue by allowing the physician to navigate procedures while seated comfortably at a remote workstation away from the radiation field and without wearing heavy lead as required in conventional endovascular procedures.
The Magellan Robotic Catheter 9Fr and 10Fr allow for independent, robotic control of two telescoping catheters (an outer Guide and an inner Leader catheter), as well as robotic manipulation of standard guide wires.
The Magellan Robotic Catheter 6Fr allows for independent robotic control of two separate bend sites on a single catheter, as well as robotic manipulation of standard guide wires. This smaller catheter design may be preferred by certain physicians who prefer a smaller diameter vessel access site, or in procedures in smaller vessels.
The Magellan Robotic Catheter eKit provides robotic control of 3rd party microcatheters through a robotic catheter with dual-bend technology. This configuration may provide an additional level of robotic control during procedures in which therapy is delivered through a microcatheter.
About Hansen Medical, Inc.
Hansen Medical, Inc., based in Mountain View, California, is the global leader in Intravascular Robotics, developing products and technology designed to enable the accurate positioning, manipulation and control of catheters and catheter-based technologies. The Company's Magellan™ Robotic System, Magellan Robotic Catheters, and related accessories are intended to facilitate navigation to anatomical targets in the peripheral vasculature and subsequently provide a conduit for manual placement of therapeutic devices. The Company's mission is to enable cardiac arrhythmia and endovascular procedures and to improve patient outcomes through the use of intravascular robotics. Additional information can be found at www.hansenmedical.com
"Hansen Medical," "Hansen Medical (with Heart Design)," and "Heart Design (Logo)" are registered trademarks, and "Magellan" and "Hansen Medical Magellan" are trademarks of Hansen Medical, Inc. in the U.S. and other countries. All other trademarks are the property of their respective owners.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements containing the words "plan," "expects," "potential," "believes," "goal," "estimate," "anticipates," and other similar words. These statements are based on the current estimates and assumptions of our management as of the date of this press release and are subject to risks, uncertainties, changes in circumstances and other factors that may cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Examples of such statements include statements regarding the potential benefits of our robotic systems for hospitals, patients and physicians. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others: factors relating to engineering, regulatory, manufacturing, sales and customer service challenges in developing new products and entering new markets; potential safety and regulatory issues that could slow or suspend our sales; the effect of credit, financial and economic conditions on capital spending by our potential customers; the rate of adoption of our systems and the rate of use of our catheters; our ability to manage expenses and cash flow, and obtain adequate financing; and other risks more fully described in the "Risk Factors" in Hansen Medical's Quarterly Report on Form 10-Q for the quarter ended September 30, 2015 and Hansen Medical's other filings with the Securities and Exchange Commission. Given these uncertainties, you should not place undue reliance on the forward-looking statements in this press release. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
1 U.S. Environmental Protection Agency of Radiation Protection Programs Home Page; Health Effects, http://www.epa.gov/rpdweb00/understand/health_effects.html
(Accessed on November 10, 2014)
2 Robotic Catheter Assistance: The Relationship on Radiation Exposure, presentation by Barry Katzen, MD during Charing Cross International Symposium, London, April 29, 2015.